Lenalidomide versus Thalidomide or Bortezomib as maintenance regimen for non-transplant patients with multiple myeloma: multi-center real world experiences in China

被引：0

作者：

Zhuang, Zhe ^{[1
]}

Shi, Lei ^{[2
]}

Tian, Ying ^{[3
]}

Zou, Dongmei ^{[4
]}

Feng, Ru ^{[5
]}

Dong, Fei ^{[6
]}

Ma, Yanping ^{[7
]}

Yu, Hong ^{[8
]}

Tian, Wei-wei ^{[9
]}

Liu, Shuangjiao ^{[1
]}

Ma, Liang-Ming ^{[10
]}

Fu, Rong ^{[8
]}

Jing, Hongmei ^{[6
]}

Liu, Hui

Sun, Wanling ^{[4
]}

Chen, Wenming ^{[3
]}

Wu, Yin ^{[3
]}

Bao, Li ^{[2
]}

Zhuang, Junling ^{[1
]}

机构：

[1] Chinese Acad Med Sci, Dept Hematol, Peking Union Med Coll Hosp, Beijing, Peoples R China

[2] Beijing Jishuitan Hosp, Dept Hematol, Beijing, Peoples R China

[3] Capital Med Univ, Dept Hematol, Beijing Chao Yang Hosp, Beijing, Peoples R China

[4] Capital Med Univ, Dept Hematol, Xuanwu Hosp, Beijing, Peoples R China

[5] Chinese Acad Med Sci, Beijing Hosp, Inst Geriatr Med, Dept Hematol, Beijing, Peoples R China

[6] Peking Univ Third Hosp, Dept Hematol, Beijing, Peoples R China

[7] Shanxi Med Univ, Dept Hematol, Hosp 2, Taiyuan, Peoples R China

[8] Tianjin Med Univ, Dept Hematol, Gen Hosp, Tianjin, Peoples R China

[9] Shanxi Med Univ, Dept Hematol, Shanxi Bethune Hosp, Taiyuan, Peoples R China

[10] Shanxi Med Univ, Hosp 2, Dept Hematol, Taiyuan, Peoples R China

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-141

引用

页码：S112 / S113

页数：2

共 50 条

[1] Lenalidomide Versus Thalidomide or Bortezomib As Maintenance Regimens for Non-Transplant Patients with Multiple Myeloma: Multi-Center Real World Experience in China
Zhuang, Zhe
Shi, Lei
Tian, Ying
Zou, Dongmei
Feng, Ru
Dong, Fei
Ma, Yanping
Yu, Hong
Tian, Weiwei
Liu, Shuangjiao
Ma, Liangming
Fu, Rong
Jing, Hongmei
Liu, Hui
Sun, Wanling
Chen Wenming
Wu, Yin
Bao, Li
Zhuang, Junling
BLOOD, 2021, 138
[2] Ixazomib versus lenalidomide or ixazomib and lenalidomide combination as maintenance regimen for transplant-ineligible multiple myeloma: update of a multi-center prospective study in China
Zhuang, Zhe
Tian, Ying
Yu, Hong
Shi, Lei
Tian, Wei-wei
Liu, Qinhua
Zou, Dongmei
Dong, Fei
Feng, Ru
Ma, Yanping
Liu, Shuangjiao
Liu, Hui
Jing, Hongmei
Sun, Wanling
Ma, Liang-Ming
Bao, Li
Fu, Rong
Wu, Yin
Chen, Wenming
Zhuang, Junling
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S104 - S104
[3] Ixazomib versus lenalidomide or ixazomib and lenalidomide combination as maintenance regimen for patients with multiple myeloma: interim analysis of a multi-center prospective study in China
Zhuang, Zhe
Tian, Ying
Yu, Hong
Shi, Lei
Tian, Wei-wei
Liu, Qinhua
Zou, Dongmei
Dong, Fei
Ma, Yanping
Feng, Ru
Liu, Shuangjiao
Liu, Hui
Jing, Hongmei
Sun, Wanling
Ma, Liang-Ming
Bao, Li
Wu, Yin
Chen, Wenming
Zhuang, Junling
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S54 - S55
[4] Ixazomib versus Lenalidomide or Ixazomib and Lenalidomide combination as maintenance regimen for patients with multiple myeloma: interim analysis of a multi-center prospective study in China
Zhuang, Zhe
Yu, Hong
Liu, Qinhua
Zou, Dongmei
Shi, Lei
Tian, Ying
Dong, Fei
Ma, Yanping
Tian, Wei-wei
Feng, Ru
Liu, Shuangjiao
Liu, Hui
Ma, Liang-Ming
Jing, Hongmei
Chen, Wenming
Wu, Yin
Bao, Li
Sun, Wanling
Fu, Rong
Zhuang, Junling
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S113 - S113
[5] Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimen for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China
Zhe Zhuang
Ying Tian
Hong Yu
Lei Shi
Tian, Wei-wei
Liu, Qinhua
Zou, Dongmei
Fei Dong
Ma, Yanping
Ru Feng
Liu, Shuangjiao
Hui Liu
Jing, Hongmei
Sun, Wanling
Ma, Liangming
Li Bao
Rong Fu
Yin Wu
Chen Wenming
Zhuang, Junling
BLOOD, 2022, 140 : 12637 - 12639
[6] MAINTENANCE TREATMENT WITH THALIDOMIDE AFTER A FIRST LINE WITH BORTEZOMIB IN PATIENTS DIAGNOSED WITH MULTIPLE MYELOMA NON-TRANSPLANT CANDIDATES. EXPERIENCE OF A SINGLE CENTER
De Miguel Llorente, D.
Perez Gil, A.
Golbano Lopez, N.
Guillen Garcia, H.
Vazquez Ramo, A.
Perez Ortega, A.
Arbeteta Juanis, J.
Subira Perez, D.
Morales Sanz, M. D.
Juarez Salcedo, L. M.
Herrero Martin, S.
HAEMATOLOGICA, 2018, 103 : 306 - 306
[7] Lenalidomide or bortezomib as maintenance treatment remedy the inferior impact of high-risk cytogenetic abnormalities in non-transplant patients with newly diagnosed multiple myeloma: a real-world multi-centered study in China
Zhuang, Zhe
Tian, Ying
Shi, Lei
Zou, Dongmei
Feng, Ru
Tian, Wei-wei
Yu, Hong
Dong, Fei
Liao, Aijun
Ma, Yanping
Liu, Qinhua
Liu, Shuangjiao
Jing, Hongmei
Fu, Rong
Ma, Liang-ming
Liu, Hui
Sun, Wanling
Bao, Li
Wu, Yin
Chen, Wenming
Zhuang, Junling
FRONTIERS IN ONCOLOGY, 2023, 13
[8] Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimens for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China
Zhuang, Zhe
Tian, Ying
Tian, Wei-wei
Yu, Hong
Zou, Dongmei
Liu, Qinhua
Shi, Lei
Dong, Fei
Ma, Yanping
Feng, Ru
Liu, Shuangjiao
Liu, Hui
Jing, Hongmei
Bao, Li
Sun, Wanling
Fu, Rong
Ma, Liangming
Chen Wenming
Wu, Yin
Zhuang, Junling
BLOOD, 2021, 138
[9] Cyclophosphamide, Bortezomib and Dexamethasone (CyBORD) Is a Feasible and Active Regimen for Non-Transplant Eligible Multiple Myeloma Patients
Zepeda, Victor H. Jimenez
Duggan, Peter
Neri, Paola E.
Bahlis, Nizar J.
BLOOD, 2014, 124 (21)
[10] Analysis of frontline treatment of non-transplant elderly myeloma patients in Wales: comparison of bortezomib versus lenalidomide based treatment
Bygrave, C.
Hogan, F.
Mahdi, E.
Downing, A.
Simmons, A.
Burton, T.
Atkinson, A.
Goringe, A.
Jackson, H.
Murray, J.
Sati, H.
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 117 - 117

← 1 2 3 4 5 →